ScholarIQanswers from OpenAlex
AstraZeneca (Singapore)
InstitutionResearch output, impact & collaborations
AstraZeneca (Singapore) is a institution indexed in ScholarIQ from OpenAlex.
What is known about AstraZeneca (Singapore)?
ScholarIQrecord summary
AstraZeneca (Singapore) is a research organisation in Singapore, SG. OpenAlex records 3,046 works and 250,731 citations for it. 1,586 researchers list it as their most recent affiliation.
How many works does AstraZeneca (Singapore) have?
ScholarIQindexed works
AstraZeneca (Singapore) has 3,046 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does AstraZeneca (Singapore) have?
ScholarIQcitation count
AstraZeneca (Singapore) has 250,731 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at AstraZeneca (Singapore)?
ScholarIQresearcher count
AstraZeneca (Singapore) has 1,586 researchers in the ScholarIQ index.
What is the average h-index at AstraZeneca (Singapore)?
ScholarIQavg h-index
AstraZeneca (Singapore) has an average h-index of 68.3 in OpenAlex.
What is the ROR of AstraZeneca (Singapore)?
ScholarIQror
The ROR for AstraZeneca (Singapore) is on the source record.
What is the OpenAlex record for AstraZeneca (Singapore)?
ScholarIQopenalex
The OpenAlex for AstraZeneca (Singapore) is on the source record.
Who are the most-cited researchers behind AstraZeneca (Singapore)?
ScholarIQtop researchers by citations
What are the most-cited papers on AstraZeneca (Singapore)?
ScholarIQmost cited works
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Deborah Nejman, Ilana Livyatan, Garold Fuks, Nancy Gavert, Yaara Zwang, Leore T. Geller, Aviva Rotter-Maskowitz, Roi Weiser, Giuseppe Mallel, Elinor Gigi, Arnon Meltser, Gavin M. Douglas, Iris Kamer, Vancheswaran Gopalakrishnan, Tali Dadosh, Smadar Levin‐Zaidman, Sofia Avnet, Tehila Atlan, Zachary A. Cooper, Reetakshi Arora, Alexandria P. Cogdill, Md Abdul Wadud Khan, Gabriel O Ologun, Yuval Bussi, Adina Weinberger, Maya Lotan‐Pompan, Ofra Golani, Gili Perry, Merav Rokah, Keren Bahar‐Shany, Elisa A. Rozeman, Christian U. Blank, Anat Ronai, Ron Shaoul, Amnon Amit, Tatiana Dorfman, Ran Kremer, Zvi R. Cohen, Sagi Harnof, Tali Siegal, Einav Yehuda‐Shnaidman, Einav Nili Gal‐Yam, Hagit Shapira, Nicola Baldini, Morgan G. I. Langille, Alon Ben‐Nun, Bella Kaufman, Aviram Nissan, Talia Golan, Maya Dadiani, Keren Levanon, Jair Bar, Shlomit Yust‐Katz, Iris Barshack, Daniel S. Peeper, Dan J. Raz, Eran Segal, Jennifer A. Wargo, Judith Sandbank, Noam Shental, Ravid Straussman
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Moshe Sade-Feldman, Keren Yizhak, Stacey L. Bjorgaard, John P. Ray, Carl G. de Boer, Russell W. Jenkins, David Lieb, Jonathan Chen, Dennie T. Frederick, Michal Barzily-Rokni, Samuel S. Freeman, Alexandre Reuben, Paul Hoover, Alexandra–Chloé Villani, Elena V. Ivanova, Andrew Portell, Patrick H. Lizotte, Amir Reza Aref, Jean-Pierre Eliane, Marc R. Hammond, Hans Vitzthum, Shauna Blackmon, Bo Li, Vancheswaran Gopalakrishnan, Sangeetha M. Reddy, Zachary A. Cooper, Cloud P. Paweletz, David A. Barbie, Anat Stemmer‐Rachamimov, Keith T. Flaherty, Jennifer A. Wargo, Genevieve M. Boland, Ryan J. Sullivan, Gad Getz, Nir Hacohen
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
Leore T. Geller, Michal Barzily-Rokni, Tal Danino, Oliver Jonas, Noam Shental, Deborah Nejman, Nancy Gavert, Yaara Zwang, Zachary A. Cooper, Kevin Shee, Christoph A. Thaiss, Alexandre Reuben, Jonathan Livny, Roi Avraham, Dennie T. Frederick, Matteo Ligorio, Kelly Chatman, Stephen Johnston, Carrie M. Mosher, Alexander Brandis, Garold Fuks, Candice R. Gurbatri, Vancheswaran Gopalakrishnan, Michael P. Kim, Mark W. Hurd, Matthew H. G. Katz, Jason B. Fleming, Anirban Maitra, David A. Smith, Matt Skalak, Jeffrey Bu, Monia Michaud, Sunia A. Trauger, Iris Barshack, Talia Golan, Judith Sandbank, Keith T. Flaherty, Anna Mandinova, Wendy S. Garrett, Sarah P. Thayer, Cristina R. Ferrone, Curtis Huttenhower, Sangeeta N. Bhatia, Dirk Gevers, Jennifer A. Wargo, Todd R. Golub, Ravid Straussman
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Weiyi Peng, Jie Qing Chen, Chengwen Liu, Shruti Malu, Caitlin Creasy, Michael T. Tetzlaff, Chunyu Xu, Jodi A. McKenzie, Chunlei Zhang, Xiaoxuan Liang, Leila J. Williams, Wanleng Deng, Guo Chen, Rina M. Mbofung, Alexander J. Lazar, Carlos A. Torres‐Cabala, Zachary A. Cooper, Pei-Ling Chen, Trang N. Tieu, Stefani Spranger, Xiaoxing Yu, Chantale Bernatchez, Marie‐Andrée Forget, Cara Haymaker, Rodabe N. Amaria, Jennifer L. McQuade, Isabella C. Glitza, Tina Cascone, Haiyan S. Li, Lawrence N. Kwong, Timothy P. Heffernan, Jianhua Hu, Roland L. Bassett, Marcus Bosenberg, Scott E. Woodman, Willem W. Overwijk, Gregory Lizée, Jason Roszik, Thomas F. Gajewski, Jennifer A. Wargo, Jeffrey E. Gershenwald, Laszlo Radvanyi, Michael A. Davies, Patrick Hwu
Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices
Felicia V. So, Najla Guthrie, Ann F. Chambers, Madeleine Moussa, Kenneth K. Carroll
How much of the research on AstraZeneca (Singapore) is open access?
ScholarIQopen access share
75%OPEN ACCESS